+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

BioInvent International AB (BINV) - Financial and Strategic SWOT Analysis Review

  • ID: 1292321
  • SWOT Analysis
  • June 2020
  • Region: Global
  • 54 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Ablynx NV
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • Dyax Corp
  • Genentech Inc
  • Genmab AS
  • MORE
BioInvent International AB (BINV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

BioInvent International AB (BioInvent) focuses on the research and development of antibodies for the treatment of cancer. The company uses n-CoDeR, its inhouse platform for developing immuno-oncology drugs. n-CoDeR is an antibody library used for the rapid selection, screening and identification of antibodies. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers. The company has collaborations and partners with several leading pharmaceutical companies including Pfizer, MSD and Transgene for the co-development of its drug candidates. BioInvent is headquartered in Lund, Sweden.

BioInvent International AB Key Recent Developments

Jun 22, 2020: BioInvent presents proof-of-concept data for two TNFR2-targeting antibodies
May 15, 2020: BioInvent expands anti-TNFR2 program by selecting second monoclonal antibody for further development
Apr 30, 2020: BioInvent signs new manufacturing agreement with U.S. Cell Therapy company
Apr 28, 2020: BioInvent Interim Report January 1 - March 31, 2020
Mar 03, 2020: BioInvent and Transgene to present data on BT-001, an oncolytic virus encoding for an anti-CTLA4 antibody, at upcoming congresses

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ablynx NV
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • Dyax Corp
  • Genentech Inc
  • Genmab AS
  • MORE
Section 1 - About the Company
  • BioInvent International AB - Key Facts
  • BioInvent International AB - Key Employees
  • BioInvent International AB - Key Employee Biographies
  • BioInvent International AB - Major Products and Services
  • BioInvent International AB - History
  • BioInvent International AB - Company Statement
  • BioInvent International AB - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • BioInvent International AB - Business Description
  • Product Category: Revenues from Collaboration Agreements
  • Performance
  • Product Category: Revenues from External Development Projects
  • Performance
  • Product Category: Revenues from Technology Licenses
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Other Countries
  • Performance
  • Geographical Segment: Sweden
  • Performance
  • Geographical Segment: USA
  • Performance
  • BioInvent International AB - Corporate Strategy
  • BioInvent International AB - SWOT Analysis
  • SWOT Analysis - Overview
  • BioInvent International AB - Strengths
  • BioInvent International AB - Weaknesses
  • BioInvent International AB - Opportunities
  • BioInvent International AB - Threats
  • BioInvent International AB - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • BioInvent International AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Jun 22, 2020: BioInvent presents proof-of-concept data for two TNFR2-targeting antibodies
  • May 15, 2020: BioInvent expands anti-TNFR2 program by selecting second monoclonal antibody for further development
  • Apr 30, 2020: BioInvent signs new manufacturing agreement with U.S. Cell Therapy company
  • Apr 28, 2020: BioInvent Interim Report January 1 - March 31, 2020
  • Mar 03, 2020: BioInvent and Transgene to present data on BT-001, an oncolytic virus encoding for an anti-CTLA4 antibody, at upcoming congresses
  • Feb 27, 2020: BioInvent financial statement January 1 - December 31, 2019
  • Aug 22, 2019: BioInvent: Interim report January 1 - June 30, 2019
  • Jul 31, 2019: BioInvent announces selection of first target discovered by BioInvent’s proprietary F.I.R.S.T technology platform under collaboration with Pfizer
  • May 22, 2019: BioInvent interim report January 1 - March 31, 2019
  • Apr 26, 2019: BioInvent receives €0.75 million milestone under Mitsubishi Tanabe Pharma partnership
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact
  • Disclaimer
List of Tables
  • BioInvent International AB, Key Facts
  • BioInvent International AB, Key Employees
  • BioInvent International AB, Key Employee Biographies
  • BioInvent International AB, Major Products and Services
  • BioInvent International AB, History
  • BioInvent International AB, Subsidiaries
  • BioInvent International AB, Key Competitors
  • BioInvent International AB, Ratios based on current share price
  • BioInvent International AB, Annual Ratios
  • BioInvent International AB, Annual Ratios (Cont...1)
  • BioInvent International AB, Interim Ratios
  • BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • BioInvent International AB, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • BioInvent International AB, Performance Chart (2015 - 2019)
  • BioInvent International AB, Ratio Charts
  • BioInvent International AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • BioInvent International AB, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Genentech Inc
  • Seattle Genetics Inc
  • Genmab AS
  • Bristol-Myers Squibb Co
  • Amgen Inc
  • Pfizer Inc
  • Merck & Co Inc
  • Double Bond Pharmaceutical International AB
  • Dyax Corp
  • Ablynx NV
Note: Product cover images may vary from those shown
Adroll
adroll